PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., a leading provider of clinical development technology, today announced Medable AI – generative AI capabilities that help sponsors and clinical research organizations (CROs) build digital and decentralized trials faster with complete visibility and control over technology setup. Medable is the first to incorporate generative AI in the study build process, ultimately driving the industry to a breakthrough, one-day study startup.
Medable AI integrated in Medable Studio automates repetitive, time-intensive manual tasks to decrease time to First Patient In (FPI) for digital and decentralized clinical trials, dramatically accelerating study startup. Building out multiple outcomes assessments for a study traditionally takes days but can now be completed in 30 minutes, based on early metrics. Medable AI also provides users with greater transparency and control over trial builds with advanced features.
Part of a broader AI strategy, Medable AI will initially deliver many new capabilities, such as automatically converting existing outcomes assessments into fully digital eCOAs in seconds. Users can also easily edit assessments with a simple ChatGPT-like integrated prompt interface and generate and scale assessments of varying complexity and logic.
“We are proud to showcase our AI capabilities within the Medable platform and, through Studio, eliminate one of the biggest hurdles to broad adoption of digital and decentralized clinical trials,” said Tim Smith, Chief Technology Officer at Medable. “Studio is just the start of an aggressive roadmap rolling out in 2025 as we continue to transform the way clinical research is conducted.”
Medable AI-integrated Studio platform will be generally available in December 2024. Contact media@medable.com to learn more or access it on Google Cloud Marketplace.
Medable, which ranked in both 2023 and 2024 on the Inc. 5000, has deployed its software-as-a-service platform in more than 300 decentralized and hybrid clinical trials in 70 countries, serving more than one million patients and research participants globally. Customers have achieved impressive results – including 90% eCOA adherence and 50% cost reductions. A Tufts CSDD study also shows that, on average, decentralized trials can achieve net financial benefits from five to 13 times for Phase II and Phase III trials, equating to roughly $10 million ROI and $39 million ROI for an investment on average of $500K in Phase II and $1.5M in Phase III trials, respectively.
“Medable is excited to leverage AI in our mission to make clinical trials more accessible to more patients,” said Dr. Michelle Longmire, CEO and co-founder of Medable. “We are focused on step function change – true innovation, not iteration. As fast as the world is changing, this is critical, and we are starting by taking eCOA and DCT off the critical path. This is just the beginning.”
Learn more about how Medable AI is improving clinical trials at the Decentralized Trials and Research Alliance’s (DTRA’s) Annual Meeting, Friday Nov 15 when executives from Medable and GSK will host a fireside chat and at 3:15 for a demo of Medable Studio.
About Medable
Medable is on a mission to get effective therapies to people faster. Its digital clinical trials platform enhances speed, scale, and patient access in clinical research, accelerating medicines for thousands of conditions without treatment or cure. Awarded Best Digital Health Solution by the Galien Foundation, Medable’s platform has been deployed in nearly 400 trials in 70 countries and 120 languages, serving more than one million patients globally. Medable is a privately held, venture-backed company headquartered in Palo Alto, California, and was listed for the second year in a row on the Inc. 5000 in 2024.
